Skip to main content

Table 2 Risk of common adverse events for discrete time periods following initiation of therapy

From: Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

Time interval Treatment arm Adverse event
   Cough Diarrhoea Vomiting
   Risk* HR (95% CI) p-value Risk* HR (95% CI) p-value Risk* HR (95% CI) p-value
1-3 days AL 7.8% 1.14 (0.71-1.84) 0.59 4.1% 1.13 (0.59-2.19) 0.71 1.2% 1.36 (0.41-4.44) 0.61
  DP 8.9%    4.7%    1.7%   
4-28 days AL 39.8% 1.17 (0.93-1.48) 0.18 18.5% 0.81 (0.57-1.15) 0.23 2.1% 2.10 (0.92-4.79) 0.08
  DP 47.1%    15.1%    4.4%   
28-63 days AL 51.9% 0.99 (0.68-1.46) 0.97 22.1% 0.90 (0.53-1.53) 0.70 11.6% 0.70 (0.34-1.43) 0.33
  DP 47.1%    18.9%    7.4%   
  1. * Cumulative risk during time interval of interest estimated using the Kaplan-Meier product limit formula
  2. HR = hazard ratio for DP vs. AL, generated using multivariate Cox proportional hazard models adjusted for repeated measures in the same patient
\